MICROTECH MED-B (02235.HK): Next-generation CGM AiDEX G9 obtains NMPA registration approval for marketing
NewTimeSpace News: On 7 September 2026, MicroTech Medical (Hangzhou) Co., Ltd. (stock code: 02235) voluntarily announced that its next-generation patch-style continuous glucose monitoring (CGM) system, AiDEX G9, had recently obtained marketing approval from the National Medical Products Administration (NMPA).
The announcement stated that AiDEX G9 represents an innovative change in technical architecture compared with the first-generation patch-style product, with comprehensive upgrades in size, lightweight design and wearing comfort, offering diabetic patients a lighter and more convenient experience in blood glucose management.
The announcement cited data from the International Diabetes Federation (IDF) "Diabetes Atlas 2025" that China is one of the largest diabetes markets in the world, with approximately 148 million adults aged 20-79 living with diabetes in 2024, ranking first globally, and a further 274 million adults with prediabetes. The approval will further enrich the group's product pipeline, broaden user coverage and help the group capture opportunities in the Chinese market, consolidating and enhancing its market position and competitive advantages in continuous glucose monitoring. The company reminded that the production, sales and related revenue of the product are subject to various factors including market changes, and that shareholders and potential investors should exercise caution when dealing in the company's shares.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- MICROTECH MED-B (02235.HK): Enters Raw Material Purchase Framework Agreement with Connected Person Hangzhou Shukang
- ETF Financing Ranking | Bosera NASDAQ 100 ETF(QDII) (513390) had a net financing buy-in of CNY 33.91 million, ranked first among comparable funds
- ETF Financing Ranking | Bosera NASDAQ 100 ETF(QDII) (513390) had a net financing buy-in of CNY 21.11 million on Jul 27, ranked top among comparable funds
- MicroTech Medical(02235.HK): Continuous Glucose Monitoring System Secures Marketing Approval in South Korea
